Acetyl L-Carnitine scientific studies
The amino acid acetyl L-carnitine has gathered attention from scientists around the world as a possible supplement in the treatment of lessening the effects of neuropathy.
Researchers (5) have said that, “Complications of diabetic peripheral neuropathy (DPN) as it continues its natural course, produce increasing pain and discomfort, loss of sensation, ulcers, infections, amputations and even death.”
Scientific evidence has showed the promise of acetyl L-carnitine supplements in several studies, although the evidence is not conclusive enough to list it as a cure for the condition.
One paper (4) noted, “The current evidence suggests that acetyl L-carnitine seems effective and safe in the treatment of peripheral nerve neuropathy, especially of diabetic peripheral nerve neuropathy.”
Another study (5) stated, “Clinical trials in the last two decades have demonstrated that the use of specific nutrients can correct some of these metabolic derangements, improving symptom control and providing further benefits such as improved sensorium, blood flow and nerve regeneration. We will discuss the evidence on lipoic acid, acetyl-L-carnitine, benfotiamine and the combination of active B vitamins L-methylfolate, methylcobalamin and piridoxal-6-phosphate.”
Acetyl L-carnitine can be purchased without a prescription and tried as a supplement under the supervision of a licensed practitioner to test if it has any merit.
- Targeting neuropathic pain: Consider these alternatives
Journal of Family Practice 2015 Aug;64(8):470-5 - Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?
World Journal of Diabetes 2015 Mar 15;6(2):245–258 - Acetyl L-Carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond.
Expert Rev Neurother 2013 Aug;13(8):925-36 - Acetyl L-Carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta-analysis of randomized controlled trials
Public Library of Science. 2015 Mar 9;10(3):e0119479 - Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control
Current Clinical Pharmacology. 2011 Nov; 6(4): 260–273.